OptimizeRx Announces Pricing of Public Offering of Common Stock
05 Juni 2019 - 2:50PM
OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of
digital health messaging for the pharmaceutical industry, today
announced the pricing of the previously announced underwritten
public offering of 1,538,500 shares of its common stock, at a
public offering price of $13.00 per share. The gross proceeds to
OptimizeRx from the offering, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by OptimizeRx, are expected to be approximately $20.0 million.
In connection with the offering, OptimizeRx granted the
underwriters a 30-day option to purchase up to an additional
230,775 shares of its common stock at the public offering price,
less the underwriting discount and commissions. The offering is
expected to close on or about June 7, 2019, subject to customary
closing conditions.
The net proceeds of the offering will be used for general
corporate purposes, which may include future acquisitions.
OptimizeRx does not have any immediate arrangements, commitments or
understandings regarding any future acquisitions.
William Blair & Company, L.L.C. is acting as sole
book-running manager for the offering. B. Riley FBR is acting as
lead manager for the offering.
Roth Capital Partners and Lake Street Capital Markets, LLC are
acting as financial advisors for the offering.
The shares of common stock described above are being offered
pursuant to a shelf registration statement on Form S-3 (File No.
333-228357) that was originally filed with the Securities and
Exchange Commission (the “SEC”) on November 13, 2018 and declared
effective by the SEC on December 11, 2018. The offering is
being made only by means of a prospectus supplement and the
accompanying prospectus. Before you invest, you should read the
prospectus in the registration statement, the preliminary
prospectus supplement, and other documents OptimizeRx has filed
with the SEC for more complete information about
OptimizeRx and the offering. Copies of the registration statement,
the preliminary prospectus supplement and accompanying base
prospectus may be obtained on the SEC’s website at
http://www.sec.gov or from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606; Phone: (800) 621-0687; Email:
prospectus@williamblair.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About OptimizeRx
OptimizeRx® (Nasdaq: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest point-of-prescribe
promotional platform for the pharmaceutical industry, OptimizeRx
provides a direct channel for pharma companies to communicate with
healthcare providers right within their workflow. The cloud-based
solution supports patient adherence to medications with real-time
access to financial assistance, prior authorization, education and
critical clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications platform.
Important Cautions Regarding Forward-Looking
Statements
Certain information contained in this press release includes
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995, including statements
related to the proposed public offering, the filing of the
registration statement and the expected use of the net proceeds
from the offering. We may, in some cases use terms such as
“expects,” “plans,” “will” or other words that convey uncertainty
of the future events or outcomes to identify these forward-looking
statements. Our forward-looking statements are based on current
expectations that involve risks, potential changes in
circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the public offering on the anticipated terms, or at
all. For a further description of the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to our
business in general, please refer to our prospectus supplement
filed with the Securities and Exchange Commission (SEC) on June 4,
2019 under the heading “Risk Factors” and those documents
incorporated by reference therein, which includes our Annual Report
on Form 10-K filed with the SEC on March 12, 2019. You are
cautioned not to place undue reliance on these forward-looking
statements, which are made only as of the date of this press
release. We undertake no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.
OptimizeRx ContactDoug Baker, CFOTel (248)
651-6568 x807dbaker@optimizerx.com
Media Relations ContactNicole Brooks, Innsena
CommunicationsTel (860) 800-2344nicolebrooks@innsena.com
Investor Relations ContactRon Both, CMATel
(949) 432-7557oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024